GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in four out of four previous third-party randomized, placebo-controlled studies in generalized anxiety ...
Buccal drug delivery systems represent an innovative strategy for the administration of therapeutic agents via the oral mucosa. This approach bypasses the hepatic first‐pass metabolism, thereby ...
GlyphAgo is designed to overcome a key limitation of agomelatine by shifting absorption toward the intestinal lymphatics, avoiding first-pass liver metabolism, and increasing systemic exposure of the ...
Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers GlyphAgo is an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback